199 related articles for article (PubMed ID: 37111716)
1. Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na).
Monfort-Vengut A; de Cárcer G
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111716
[TBL] [Abstract][Full Text] [Related]
2. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.
Prasad A; Khudaynazar N; Tantravahi RV; Gillum AM; Hoffman BS
Oncotarget; 2016 Nov; 7(48):79388-79400. PubMed ID: 27764820
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.
Dietrich P; Freese K; Mahli A; Thasler WE; Hellerbrand C; Bosserhoff AK
Oncotarget; 2018 Jan; 9(3):3605-3618. PubMed ID: 29423069
[TBL] [Abstract][Full Text] [Related]
5. A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent.
Baker SJ; Cosenza SC; Athuluri-Divakar S; Reddy MVR; Vasquez-Del Carpio R; Jain R; Aggarwal AK; Reddy EP
Mol Cell; 2020 Jul; 79(1):180-190.e4. PubMed ID: 32619468
[TBL] [Abstract][Full Text] [Related]
6. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.
Hyoda T; Tsujioka T; Nakahara T; Suemori S; Okamoto S; Kataoka M; Tohyama K
Cancer Sci; 2015 Mar; 106(3):287-93. PubMed ID: 25580850
[TBL] [Abstract][Full Text] [Related]
7. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
8. Centmitor-1, a novel acridinyl-acetohydrazide, possesses similar molecular interaction field and antimitotic cellular phenotype as rigosertib, on 01910.Na.
Mäki-Jouppila JH; Laine LJ; Rehnberg J; Narvi E; Tiikkainen P; Hukasova E; Halonen P; Lindqvist A; Kallio L; Poso A; Kallio MJ
Mol Cancer Ther; 2014 May; 13(5):1054-66. PubMed ID: 24748653
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Navada SC; Silverman LR
Expert Rev Anticancer Ther; 2016 Aug; 16(8):805-10. PubMed ID: 27400247
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of
Zhou X; Xiao Q; Fu D; Zhang H; Tang Y; He J; Hu Y; Kong X; Teng F; Liu X; Yuan Y; Ding K
Cancer Biol Med; 2021 Aug; 19(2):213-28. PubMed ID: 34347396
[TBL] [Abstract][Full Text] [Related]
11. Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Atanasova VS; Pourreyron C; Farshchian M; Lawler M; Brown CA; Watt SA; Wright S; Warkala M; Guttmann-Gruber C; Hofbauer JP; Fuentes I; Prisco M; Rashidghamat E; Has C; Salas-Alanis JC; Palisson F; Hovnanian A; McGrath JA; Mellerio JE; Bauer JW; South AP
Clin Cancer Res; 2019 Jun; 25(11):3384-3391. PubMed ID: 30846478
[TBL] [Abstract][Full Text] [Related]
12. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
13. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
14. Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.
Fan AC; O'Rourke JJ; Praharaj DR; Felsher DW
Expert Opin Investig Drugs; 2013 Nov; 22(11):1495-509. PubMed ID: 23937225
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent.
Jost M; Chen Y; Gilbert LA; Horlbeck MA; Krenning L; Menchon G; Rai A; Cho MY; Stern JJ; Prota AE; Kampmann M; Akhmanova A; Steinmetz MO; Tanenbaum ME; Weissman JS
Mol Cell; 2020 Jul; 79(1):191-198.e3. PubMed ID: 32619469
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer.
Ohnuma T; Lehrer D; Ren C; Cho SY; Maniar M; Silverman L; Sung M; Gretz HF; Benisovich V; Navada S; Akahoho E; Wilck E; Taft DR; Roboz J; Wilhelm F; Holland JF
Am J Cancer Res; 2013; 3(3):323-38. PubMed ID: 23841031
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies.
Bowles DW; Diamond JR; Lam ET; Weekes CD; Astling DP; Anderson RT; Leong S; Gore L; Varella-Garcia M; Vogler BW; Keysar SB; Freas E; Aisner DL; Ren C; Tan AC; Wilhelm F; Maniar M; Eckhardt SG; Messersmith WA; Jimeno A
Clin Cancer Res; 2014 Mar; 20(6):1656-65. PubMed ID: 24493827
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Ma WW; Messersmith WA; Dy GK; Weekes CD; Whitworth A; Ren C; Maniar M; Wilhelm F; Eckhardt SG; Adjei AA; Jimeno A
Clin Cancer Res; 2012 Apr; 18(7):2048-55. PubMed ID: 22338014
[TBL] [Abstract][Full Text] [Related]
19. Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma.
Kowalczyk JT; Wan X; Hernandez ER; Luo R; Lyons GC; Wilson KM; Gallardo DC; Isanogle KA; Robinson CM; Mendoza A; Heske CM; Chen JQ; Luo X; Kelly AE; Difilippantinio S; Robey RW; Thomas CJ; Sackett DL; Morrison DK; Randazzo PA; Jenkins LMM; Yohe ME
Mol Cancer Ther; 2021 Feb; 20(2):307-319. PubMed ID: 33158997
[TBL] [Abstract][Full Text] [Related]
20. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.
Anderson RT; Keysar SB; Bowles DW; Glogowska MJ; Astling DP; Morton JJ; Le P; Umpierrez A; Eagles-Soukup J; Gan GN; Vogler BW; Sehrt D; Takimoto SM; Aisner DL; Wilhelm F; Frederick BA; Varella-Garcia M; Tan AC; Jimeno A
Mol Cancer Ther; 2013 Oct; 12(10):1994-2005. PubMed ID: 23873848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]